Results to be presented during the sarcoma session at the ASCO 2018 Annual Meeting

CHICAGO, IL June 2, 2018 NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present data on cardiac function in patients treated with aldoxorubicin in combination with Doxorubicin during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.

“Our data will be beneficial for the larger scientific community as we continue our research to understand potential cancer treatments,” said Patrick Soon-Shiong, MD, founder of NantWorks. “We look forward to sharing our data at ASCO and further research endeavors.”

Presentation Details

Lack of cardiac toxicity in patients treated with Aldoxrubicin with Doxorubicin equivalent doses beyond 1000mg/m2, Abstract #11585

WHO: NantOmics, LLC

WHAT: Sarcoma Session

WHEN: June 2, 8:00-11:30 AM CST

WHERE: Hall A, McCormick Place

Presentation Summary

A total of 52 patients were enrolled in three phases of the study and results found that in 11 patients, the median cumulative doxorubicin dose prior to aldoxorubicin treatment was 158 mg/m2. The cumulative aldoxorubicin dose ranged from 1000 to 7500 mg/m2. As a result, no patient developed any sign or symptom of clinical congestive heart failure. Ventricular ejection fractions ranged from 45-74% baseline, and 50-77% at end of treatment, median being 60% both at the beginning and end of treatment. The study shows that aldoxorubicin lacks cardiotoxicity in patients treated with aldoxorubicin alone or in combination with ifosfamide/mesna. No evidence of cardiac toxicity of aldoxorubicin up to doxorubicin equivalent dose of 7500mg/m2.

About NantOmics

NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis  company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.



Jen Hodson


Henry Jackson